Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312)-Reference-Cited by-同舟云学术

Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312)

Published:2021-12-08 Issue: Volume: Page:
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Pawaskar Dipti¹,Chen Xi²,Glassman Fiona¹,May Frauke³,Roberts Anthony⁴,Biondo Mark⁴,McKenzie Andrew⁴,Nolte Marc W.³,Jusko William J.⁵,Tortorici Michael¹

Affiliation:

1. CSL Behring King of Prussia Pennsylvania USA

2. Genentech San Francisco California USA

3. CSL Behring Innovation GmbH Marburg Germany

4. CSL Limited Parkville Victoria Australia

5. School of Pharmacy and Pharmaceutical Sciences University at Buffalo Buffalo New York USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13192

Reference32 articles.

1. Factor XII in coagulation, inflammation and beyond

2. The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity

3. Factor XII – What's important but not commonly thought about

4. Factor XII: What does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis

5. A biochemical abnormality in hereditary angioneurotic edema

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathophysiological dynamics in the contact, coagulation, and complement systems during sepsis: Potential targets for nafamostat mesilate;Journal of Intensive Medicine;2024-10

2. Développement clinique des thérapeutiques anti-facteur XII ciblant la thrombo-inflammation;La Revue de Médecine Interne;2024-08

3. Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study;The Lancet Haematology;2024-06

4. Current and potentially novel antithrombotic treatment in acute ischemic stroke;Thrombosis Research;2024-04

5. Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation;Frontiers in Pharmacology;2023-12-19